Our goal is to assess the combination of Cell Painting, transcriptomics and proteomics in a variety of cell models for safety assessment, using hepatotoxicity as test case
About Us
At a Glance:
The ‘Omics for Assessing Signatures for Integrated Safety (OASIS) Consortium was officially convened in July 2023 between the non-profit Health and Environmental Sciences Institute (HESI) and the Broad Institute of Harvard and MIT. The Consortium is supported by an award from the Massachusetts Life Sciences Center (MLSC), in synergy with partnered resources and expertise from industry partners and in-kind contributions from academic, government, NGO, and biotech partners. This exciting effort engages >60 global experts in toxicology, cell biology, bioinformatics, risk assessment, and assay development from more from 15 academic institutes, 7 government agencies, 16 industry organizations, and 2 non-government organizations.
Leadership
Co-Chairs
Dr. Anne Carpenter
Broad Institute
Public Sector Lead
Dr. David Rouquie
Bayer Crop Science
AgChem Sector Co-Lead
Postdocs
Dr. Srijit Seal
Broad Institute
Dr. Jessica Ewald
Broad Institute
Steering Committee
Dr. Shantanu Singh
Broad Institute
MLSC Award Lead PI CP Data Extraction Workstream Lead
Dr. Jess LaRocca
Corteva
Compound and In vivo Data Workstream Lead, Agchem Sector Co-Lead
Dr. Josh Harrill
EPA
Study Design Workstream Lead, Public Sector Lead
Dr. Andreas Bender
Cambridge University
Integrative Data Analysis Workstream Lead
Dr. Aaron Fullerton
Genentech
Pharma Sector Co-Lead
Dr. Sabah Kadri
AbbVie
Pharma Sector Co-Lead
Dr. Nicole Kleinstreuer
NIEHS
qIVIVE Workstream co-lead
Dr. Nynke Kramer
Wageningen University
qIVIVE Workstream co-lead
Dr. Deidre Dalmas
eSTAR Chair Liaison
HESI Staff
Chrissy Crute, PhD
Connie Mitchell, MS
Syril Pettit, DrPH
Liisa Koskii, MS
Leadership
